Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/60233

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

REDUCED ABILITY TO NEUTRALIZE THE OMICRON VARIANT AMONG ADULTS AFTER INFECTION AND COMPLETE VACCINATION WITH BNT162B2, CHADOX1, OR CORONAVAC AND HETEROLOGOUS BOOSTING
Espíndola, Otávio Melo et al. | Date Issued: 2023
Author
Espíndola, Otávio Melo
Fuller, Trevon L.
Araújo, Mia Ferreira de
Tort, Luis Fernando Lopez
Guaraldo, Lusiele
Calvet, Guilherme
Resende, Paola
Bonaldo, Myrna
Whitworth, Jimmy
Smith, Chris
Siqueira, Marilda
Brasil, Patrícia
Affilliation
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Institute of the Environment and Sustainability. University of California Los Angeles. Los Angeles, USA.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil / Laboratory of Molecular Virology. Biological Sciences Department. Universidad de la República. Salto, Uruguay.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Molecular Biology. Rio de Janeiro, RJ, Brazil.
Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK.
Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Abstract
COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.
Keywords
COVID-19
Omicron variant
Complete vaccination
BNT162b2
ChAdOx1
CoronaVac
Vaccine
 
Publisher
Nature Publishing Group
Citation
ESPÍNDOLA, Otávio Melo et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, v. 13, p. 1-7, May 2023.
DOI
10.1038/s41598-023-34035-9
ISSN
2045-2322